Ewing sarcoma, Neuroblastoma, Novel agents,
Other pediatric solid tumors, Phase 1 clinical trials
Not exact matches
The multikinase angiogenesis inhibitor pazopanib was well tolerated and exhibited some responses in
pediatric patients with soft - tissue sarcomas and
other refractory
solid tumors in a phase I trial.